Close
CDMO Safety Testing 2026
Novotech

Exactech Announces Investor Presentation at Canaccord Genuity Growth Conference

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Agilent, Veeda Lifesciences Launch Biopharma Analytics Hub

Agilent Technologies and Veeda Lifesciences have announced a strategic...

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been...

Cantex and Headlamp Target MS Depression Using Lumos AI

Cantex Pharmaceuticals and Headlamp Health have entered a collaboration...
- Advertisement -

Exactech, Inc., a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials will update investors at the 2012 Canaccord Genuity Growth Conference in Boston on Tuesday, August 14, 2012.

The presentation by Exactech president David Petty and CFO Jody Phillips will begin at 11:00 a.m. ET on Tuesday, August 14, followed by a question and answer session. The company will also host one-on-one meetings with investors during the conference.

Exactechโ€™s investor presentation including updates from the second quarter 2012 will be available via live and archived webcast at http://www.hawkassociates.com/profile/exac.cfm

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactechโ€™s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactechโ€™s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.

An investment profile on Exactech may be found at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the companyโ€™s expectations or beliefs concerning future events of the companyโ€™s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the companyโ€™s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the companyโ€™s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

ย 

ย 

ย 

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

Agilent, Veeda Lifesciences Launch Biopharma Analytics Hub

Agilent Technologies and Veeda Lifesciences have announced a strategic...

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been...

Cantex and Headlamp Target MS Depression Using Lumos AI

Cantex Pharmaceuticals and Headlamp Health have entered a collaboration...

VoxCell and adMare Partner on Antibody Therapy Research

VoxCell BioInnovation Inc. and adMare BioInnovations have entered a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป